$SEPN

New Septerna (SEPN) chief medical officer reports zero share holdings

Septerna's (SEPN) new Chief Medical Officer, Rajiv Patni, filed an initial ownership report showing no share holdings or insider trades. The filing includes a Power of Attorney authorizing the submission.

Original reporting
Published Sep 3, 2026, 11:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 3, 2026, 11:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$SEPN
Neutral
high confidence
Mentioned
$SEPN
Relevance
4/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$SEPNNeutralLow
01

Why it matters

The filing is a standard regulatory requirement with no material change to ownership, offering little trading insight.

02

Market read

Minimal relevance; the disclosure confirms no insider ownership and does not affect market perception.

03

What to watch

Potential future equity grants or stock options are not disclosed in this filing.

Relevance 4/10Novelty 4/10Timing: recent filing

Background

Septerna Inc. (SEPN) filed a Form 3 to disclose that its newly appointed Chief Medical Officer, Rajiv Patni, holds no shares.

Company-level read

Ticker impact

$SEPNNeutralHigh confidence
Context

Form 3 filing shows Septerna CMO Rajiv Patni holds no shares, indicating no insider ownership change.

Expected impact

none

Evidence & confidence

The filing is a routine disclosure with no equity transaction; investors are unlikely to adjust positions.

Market effects

none

none

none

Counterpoint

Even without insider holdings, the filing confirms the executive's role, which could be viewed positively if the market values leadership stability.

Key entities

  • Septerna Inc.

    Biotech company listed under ticker SEPN.

  • Rajiv Patni

    Chief Medical Officer of Septerna.

Related articles

$SEPNMed

Septerna Highlights Business Progress and Reports Second Quarter 2026 Financial Results

Septerna, Inc. (SEPN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Septerna Highlights Business Progress and Reports Second Quarter 2026 Financial Results Phase 1 Clinical Trial Ongoing for SEP-479, an Oral Small Molecule PTH1R Agonist SEP-479 Observed Clinical Pharmacokinetic Profile Supports Once-Daily Dosing; SAD / MAD Data Expec

$MANMed

Milwaukee-based Manpower names first new CEO in more than 12 years

ManpowerGroup (MAN) appoints Becky Frankiewicz as CEO effective January 1, succeeding Jonas Prising. Frankiewicz, currently president and chief strategy officer, will be the fifth CEO in the company's history. The firm reported a $13.3M loss on $18B revenue in 2025. Prising transitions to executive chair. Frankiewicz led AI integration and North American operations.

$AAPLMed

OpenAI Makes a Serious Allegation Involving Apple

OpenAI alleges a former employee, now at Apple (AAPL), transferred 100+ files related to an unreleased product to a personal account before presenting it to Apple's leadership, potentially influencing Apple's AI hardware development. Apple denies the claims, stating it has policies to prevent such use of confidential information and found no evidence supporting OpenAI's allegations. The dispute is part of an ongoing trade-secret case between the two companies.

$FRMIMed

Fermi details $6.5 billion, 15-year TensorWave lease for 222 MW at Project Matador

Fermi (FRMI) announced a 15-year lease with TensorWave for 222 MW at Project Matador, Texas. The deal, valued at $6.5 billion, includes 2.5% annual escalators and renewal options. Fermi will develop and build the facility, with occupancy starting in Q4 2027. Estimated capex ranges from $666 million to $888 million for power and $1.56 billion to $1.87 billion for the data center. The lease is expected to close by October 31, with AMD providing credit support.